India & Russia sign 16 pacts, chart roadmap till 2030. Key takeaways on labour mobility, trade, defence & nuclear energy. Essential analysis for UPSC aspirants on bilateral ties, repo rate, labour codes & more.
Delhi High Court rejects Novo Nordisk's plea for interim injunction against Dr Reddy's Labs over semaglutide. Court cites 'evergreening', allows DRL to export. Key ruling for diabetes drug market.
A recent Delhi High Court order in the Novo Nordisk vs Dr Reddy's case highlights the complexities of Indian patent litigation. We examine the system's challenges and the push for specialized IP courts.
WHO releases its first global guideline on GLP-1 therapies for obesity, recommending drugs like semaglutide for adults with a BMI over 30. Learn about the impact, safety, and who can benefit.
Delhi High Court permits Dr Reddy's to export generic semaglutide, a major win for Indian drugmakers eyeing the booming anti-obesity market. Read the full analysis.
Novo Nordisk and Eli Lilly develop daily oral weight loss pills with 10-16% average weight loss in trials. Pending FDA approval, these could replace injections.
Shaily Engineering and Gland Pharma positioned to benefit from India's semaglutide gold rush as patent expiry opens market for generic weight-loss drugs. Discover how these companies are preparing.
Michelle Obama faces Ozempic rumors after revealing slimmer frame in Annie Leibovitz photoshoot. Social media erupts with speculation despite no evidence. Read the full story.
OneSource Pharma hikes FY28 revenue guidance to over $500 million, plans $100M expansion for weight-loss drugs like semaglutide. CEO reveals accelerated growth strategy.
Biocon's generics business surges 24% driven by weight-loss drugs liraglutide & semaglutide. CEO Siddharth Mittal reveals strategy to capture share of the booming $95 billion GLP-1 market.
In a major breakthrough for weight management, the White House has secured a deal that significantly reduces prices of popular drugs Ozempic and Wegovy, making effective weight loss treatment more accessible across India.
Discover why revolutionary weight-loss drugs aren't magic bullets for India's obesity crisis. Learn about limitations, costs, and sustainable solutions.
Former US President Donald Trump is negotiating with Novo Nordisk to offer weight-loss drugs at just $149. Discover how this could revolutionize affordable healthcare and impact India's growing obesity crisis.
Discover why molecule-based weight loss supplements are going viral among young Russians. Learn about the science, risks, and expert warnings about this concerning health trend.
Breaking news: US FDA approves Rybelsus, the groundbreaking oral weight loss medication that mimics popular injection drugs. Discover how this pill could revolutionise obesity treatment in India and worldwide.
Discover how GLP-1 receptor agonists are revolutionizing diabetes and obesity treatment. Learn the mechanism behind popular drugs like Ozempic, Mounjaro, and other game-changing medications.
Bengaluru medical experts sound alarm on diabetes drugs being misused for weight loss, highlighting dangerous side effects and long-term health risks.
Discover how revolutionary GLP-1 medications including Ozempic, Wegovy, and Mounjaro are transforming America's battle against obesity, offering new hope for sustainable weight loss.
Groundbreaking research shows popular weight-loss drug semaglutide significantly reduces heart disease risk, offering dual benefits for patients struggling with obesity and cardiovascular health.
Groundbreaking research from Pune reveals diabetes drug semaglutide significantly reduces cardiovascular risks in non-diabetic patients, offering dual benefits for weight and heart health.
New research suggests diabetes and weight loss medications like Ozempic could alter how your body processes alcohol, potentially making you feel less intoxicated. Learn what this means for users.